<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="Edited by: Mark C. Siracusa, Rutgers Biomedical and Health Sciences," exact="United States" post="Reviewed by: Keke Celeste Fairfax, The University of Utah,"/>
 <result pre="States Reviewed by: Keke Celeste Fairfax, The University of Utah," exact="United States;" post="William Horsnell, University of Cape Town, South Africa *Correspondence:"/>
 <result pre="of Utah, United States; William Horsnell, University of Cape Town," exact="South Africa" post="*Correspondence: Ayat Zawawi atzawawi@kau.edu.sa Kathryn J. Else kathryn.j.else@manchester.ac.uk This"/>
 <result pre="201). As a result, this vaccine was commercialized in the" exact="United States" post="in 1973 for canines. However, it was withdrawn after"/>
 <result pre="TLR4 agonist (GLA) are in Phase 1 trials in the" exact="United States," post="Brazil, and Africa (48, 232, 233). Co-administration of both"/>
 <result pre="of both vaccines is also undergoing a clinical trial in" exact="Gabon" post="(234). Other Hookworm Vaccine Candidates Promising results have also"/>
 <result pre="181.PritchardDWalshEQuinellRRAIKOAEdmondsPKeymerA. Isotypic variation in antibody responses in a community in" exact="Papua New Guinea" post="to larval and adult antigens during infection, and following"/>
 <result pre="variation in antibody responses in a community in Papua New" exact="Guinea" post="to larval and adult antigens during infection, and following"/>
</results>
